文献速递乳腺CT

乳腺癌对比增强锥形束乳腺CT特征:与免疫组化受体及分子亚型的相关性

Contrast-enhanced cone beam breast CT features of breast cancers: correlation with immunohistochemical receptors and molecular subtypes.
PubMed 文献 · Eur Radiol · 2020-10-02

本回顾性研究纳入211例女性240个浸润性乳腺癌,分析术前对比增强锥形束乳腺CT(CE-CBBCT)特征与免疫组化受体及分子亚型的关联。结果显示11个CE-CBBCT特征与分子亚型显著相关,联合特征区分luminal与非luminal亚型AUC=0.809,区分三阴性与HER-2富集型AUC=0.913。作者认为CE-CBBCT特征有潜力帮助预测受体状态和区分分子亚型。

要点

  • 肿瘤大小、肿块形态、毛刺征及内部强化模式有助于区分luminal与非luminal亚型(AUC=0.809)。
  • 病变类型、钙化及ΔHU可作为HER-2富集型与三阴性乳腺癌的显著指标(AUC=0.913)。
  • 共11个CE-CBBCT特征与分子亚型相关,部分特征还有助于区分免疫组化受体状态。

关键影像表现/征象

  • 分子亚型与病灶灶数、病变类型、肿瘤大小、病灶密度、内部强化模式、病灶强化程度(ΔHU)、肿块形态、毛刺征、钙化、钙化分布及病灶周围血管增多显著相关(均p < 0.005)。
  • 部分CE-CBBCT特征还有助于区分免疫组化受体状态。
  • 肿瘤大小、肿块形态、毛刺征和内部强化模式与luminal与非luminal亚型的区分相关(AUC = 0.809)。
  • 病变类型、钙化和ΔHU可作为三阴性 versus HER-2富集型亚型的显著指标(AUC = 0.913)。

诊断标准与关键数值

  • 区分luminal与非luminal亚型的多因素logistic回归模型:肿瘤大小(OR = 1.244)、肿块形态(OR = 0.311)、毛刺征(OR = 0.159)、内部强化模式(OR = 0.227),AUC = 0.809。
  • 区分三阴性 versus HER-2富集型亚型的联合CE-CBBCT特征:病变类型(OR = 0.118)、钙化(OR = 0.181)、ΔHU(OR = 0.962),AUC = 0.913。

临床应用与阅片要点

  • 作者认为CE-CBBCT特征有潜力帮助预测免疫组化受体状态并区分分子亚型,进而有助于制定个体化治疗决策和预后预测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the association of contrast-enhanced cone beam breast CT (CE-CBBCT) features, immunohistochemical (IHC) receptors, and molecular subtypes in breast cancer.

METHODS: In this retrospective study, patients who underwent preoperative CE-CBBCT and received complete IHC results were analyzed. CE-CBBCT features were evaluated by two radiologists. Observer reproducibility and feature reliability were assessed. The association between CE-CBBCT features, IHC receptors, and molecular subtypes was analyzed using the chi-square, Mann-Whitney, and Kruskal-Wallis tests. Multivariate logistic regression was performed to assess the ability of combined imaging features to discriminate molecular subtypes. ROC curve was used to evaluate prediction performance.

RESULTS: A total of 240 invasive cancers identified in 211 women were enrolled. Molecular subtypes of breast cancer were significantly associated with focality number of lesions, lesion type, tumor size, lesion density, internal enhancement pattern, degree of lesion enhancement (ΔHU), mass shape, spiculation, calcifications, calcification distribution, and increased peripheral vascularity of lesion (all p < 0.005), some of which also helped to differentiate IHC receptor status. A multivariate logistic regression model showed that tumor size (odds ratio, OR = 1.244), mass shape (OR = 0.311), spiculation (OR = 0.159), and internal enhancement pattern (OR = 0.227) were associated with differentiation between luminal and non-luminal subtypes (AUC = 0.809). Combined CE-CBBCT features, including lesion type (OR = 0.118), calcifications (OR = 0.181), and ΔHU (OR = 0.962), could be significant indicators of triple-negative versus HER-2-enriched subtypes (AUC = 0.913).

CONCLUSIONS: CE-CBBCT features have the potential to help predict IHC receptor status and distinguish molecular subtypes of breast cancer, which could in turn help to develop individual treatment decisions and prognosis predictions.

KEY POINTS: • A total of 11 CE-CBBCT features were associated with molecular subtypes, some of which also helped to differentiate IHC receptor status. • Tumor size, irregular mass shape, spiculation, and internal enhancement pattern could help identify luminal subtype. • Lesion type, calcification, and ΔHU could be significant indicators of HER-2- enriched versus triple-negative breast cancers.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Ma Y, Liu A, O'Connell AM, et al. Contrast-enhanced cone beam breast CT features of breast cancers: correlation with immunohistochemical receptors and molecular subtypes. Eur Radiol. 2020. PMID: 33009590. doi:10.1007/s00330-020-07277-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。